CoChat

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

Heresco-Levy, Uriel, Ermilov, Marina, Lichtenberg, Pesah, Bar, Gali, Javitt, Daniel C · 2004 · Biological Psychiatry

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Background Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine. In this study, we assessed whether high-dose glycine may also be therapeutically beneficial when added to olanzapine and risperidone treatment.Methods Seventeen olanzapine- or risperidone-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-week crossover treatment trial with.8 g/kg/day glycine added to their ongoing antipsychotic medication. Clinical assessments were performed biweekly throughout the study. Clinical laboratory parameters and amino acid serum levels were monitored.Results Glycine treatment was well tolerated and resulted in a significant (p <.0001) 23% +/- 8% reduction in negative symptoms. Significant improvements were also registered in cognitive and positive symptoms. The negative symptoms improvement remained significant even following covariation for changes in other symptom clusters and extrapyramidal side effects. High posttreatment glycine serum levels significantly predicted (r =.60) clinical response.Conclusions These findings indicate that the efficacy of olanzapine and risperidone may be augmented using high-dose adjuvant glycine treatment and suggest that these atypical antipsychotics may affect NMDA receptor-mediated neurotransmission differently than clozapine.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0006-3223(03)00707-8

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Research works printed but not linked: 4

  1. Barbeau, 1974, Preliminary study of glycine administration in patients with spasticity, Neurology, 24, 392
  2. Danysz, 1998, Glycine and N-methyl-D-aspartate receptors, Pharmacol Rev, 50, 597
  3. Kostakow, 1933, Glycocoll treatment of progressive muscular dystrophy, Deutsch Arch Klin Med, 175, 25
  4. Milhorat, 1933, Treatment of progressive muscular dystrophy and similar muscular disturbances with glycine, Deutsch Arch Klin Med, 174, 487

Cited by

See all 227

Metadata

Authors
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • Herzog Hospital (IL)
  • Nathan Kline Institute for Psychiatric Research (US)
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2004-01
Volume
55
Issue
2
Pages
165-171
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2068898125
Cited by
222
References
48
Citations by year
2026: 3 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 1 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 8 · 2013: 11 · 2012: 10
FWCI
12.31
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
glycine, olanzapine, risperidone, schizophrenia, NMDA receptor agonist, negative symptoms, cognitive symptoms, positive symptoms, atypical antipsychotics, adjuvant therapy, treatment response prediction, extrapyramidal symptoms
MeSH terms
Olanzapine, Adult, Behavioral Symptoms, Benzodiazepines, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Glycine, Humans, Male, Middle Aged, Pirenzepine, Schizophrenia, Serine, Time Factors, Antipsychotic Agents, Multivariate Analysis, Treatment Outcome, Cross-Over Studies, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. https://app.cochat.ai/papers/10.1016/s0006-3223(03)00707-8
The paper
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004). High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(03)00707-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.